Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA

PHASE4CompletedINTERVENTIONAL
Enrollment

504

Participants

Timeline

Start Date

May 14, 2019

Primary Completion Date

March 20, 2022

Study Completion Date

July 27, 2022

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Tripterygium Wilfordii

Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.

DRUG

Methotrexate

Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.

DRUG

Yisaipu

Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.

Trial Locations (1)

100032

Deptment of Rheumatology, Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT03589833 - Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA | Biotech Hunter | Biotech Hunter